Hims & Hers Health, Inc. Earnings Per Share Disclosure
| Year Ended December 31, | |||||||||||||||||||||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||||||||||||||||||||
| Class A | Class V | Class A | Class V | Class A | Class V | ||||||||||||||||||||||||||||||
| Numerator: | |||||||||||||||||||||||||||||||||||
| Net income (loss) attributable to common stockholders, basic | $ | 123,585 | $ | 4,780 | $ | 121,148 | $ | 4,890 | $ | (22,604) | $ | (942) | |||||||||||||||||||||||
| Amortization of debt discount and issuance costs for 2030 Convertible Notes | 3,923 | — | — | — | — | — | |||||||||||||||||||||||||||||
| Reallocation of undistributed earnings | 488 | (488) | 431 | (431) | — | — | |||||||||||||||||||||||||||||
| Net income (loss) attributable to common stockholders, diluted | 127,996 | 4,292 | 121,579 | 4,459 | (22,604) | (942) | |||||||||||||||||||||||||||||
| Denominator: | |||||||||||||||||||||||||||||||||||
| Weighted average shares outstanding, basic | 216,581,645 | 8,377,623 | 207,561,414 | 8,377,623 | 200,967,089 | 8,377,623 | |||||||||||||||||||||||||||||
| Effect of dilutive potential common shares | 33,271,279 | — | 20,869,839 | — | — | — | |||||||||||||||||||||||||||||
| Weighted average shares outstanding, diluted | 249,852,924 | 8,377,623 | 228,431,253 | 8,377,623 | 200,967,089 | 8,377,623 | |||||||||||||||||||||||||||||
| Basic net income (loss) per share | $ | 0.57 | $ | 0.57 | $ | 0.58 | $ | 0.58 | $ | (0.11) | $ | (0.11) | |||||||||||||||||||||||
| Diluted net income (loss) per share | $ | 0.51 | $ | 0.51 | $ | 0.53 | $ | 0.53 | $ | (0.11) | $ | (0.11) | |||||||||||||||||||||||
| Year Ended December 31, | ||||||||||||||||||||
| 2025 | 2024 | 2023 | ||||||||||||||||||
| RSUs | 2,660,472 | 360,601 | 15,220,986 | |||||||||||||||||
| Common stock issuable under the ESPP | 356,339 | — | 404,648 | |||||||||||||||||
| Stock options | — | 156,558 | 21,278,043 | |||||||||||||||||
| Common stock issued subject to vesting | — | — | 1,090,181 | |||||||||||||||||
| PRSUs | — | — | 928,642 | |||||||||||||||||
| Warrants to purchase Class A common stock | — | — | 561,058 | |||||||||||||||||
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.